Michael J. Labarre Sells 1,697 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded down $0.22 during trading hours on Thursday, hitting $57.70. The stock had a trading volume of 879,987 shares, compared to its average volume of 1,292,471. The company has a 50 day simple moving average of $54.08 and a two-hundred day simple moving average of $54.71. The firm has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.82, a P/E/G ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC lifted its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.